Business Description
Marinomed Biotech AG
ISIN : ATMARINOMED6
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | -0.69 | |||||
Debt-to-Equity | -2.15 | |||||
Debt-to-EBITDA | -4.84 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.25 | |||||
Beneish M-Score | -3.18 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.1 | |||||
3-Year EBITDA Growth Rate | 10.3 | |||||
3-Year EPS without NRI Growth Rate | -3.2 | |||||
3-Year FCF Growth Rate | 25.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.15 | |||||
9-Day RSI | 30.15 | |||||
14-Day RSI | 31.77 | |||||
6-1 Month Momentum % | -46.78 | |||||
12-1 Month Momentum % | -47.21 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.74 | |||||
Quick Ratio | 0.63 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 57.59 | |||||
Days Sales Outstanding | 102.5 | |||||
Days Payable | 42.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | 3.32 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 12.46 | |||||
Operating Margin % | -58.94 | |||||
Net Margin % | -73.99 | |||||
FCF Margin % | -49.31 | |||||
ROA % | -38.01 | |||||
ROIC % | -42.19 | |||||
ROC (Joel Greenblatt) % | -68.92 | |||||
ROCE % | -43.68 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.14 | |||||
EV-to-EBIT | -9.35 | |||||
EV-to-EBITDA | -10.76 | |||||
EV-to-Revenue | 5.28 | |||||
EV-to-FCF | -10.84 | |||||
Earnings Yield (Greenblatt) % | -10.69 | |||||
FCF Yield % | -15.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Marinomed Biotech AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 9.184 | ||
EPS (TTM) (€) | -4.471 | ||
Beta | 0.08 | ||
Volatility % | 41.59 | ||
14-Day RSI | 31.77 | ||
14-Day ATR (€) | 0.721608 | ||
20-Day SMA (€) | 20.31 | ||
12-1 Month Momentum % | -47.21 | ||
52-Week Range (€) | 17.9 - 46.2 | ||
Shares Outstanding (Mil) | 1.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Marinomed Biotech AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Marinomed Biotech AG Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Marinomed Biotech AG Frequently Asked Questions
What is Marinomed Biotech AG(WBO:MARI)'s stock price today?
When is next earnings date of Marinomed Biotech AG(WBO:MARI)?
Does Marinomed Biotech AG(WBO:MARI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |